Healthcare >> CEO Interviews >> September 13, 2002
LUKE M. BESHAR is Chief Financial Officer of Dendrite, which enables
pharmaceutical companies to optimize their sales and marketing channels
and clinical resources. Prior to joining the company in 2002, he served
as Executive Vice President ' Finance and CFO of Expanets, Inc, during
which time the company grew from inception to over $1 billion in revenue
in four years and provided advanced voice and data communications
solutions to businesses across the United States. Prior to joining
Expanets, Mr. Beshar served as Senior Vice President and CFO at PNY
Technologies, Inc. Earlier, he served as President, CEO, and CFO of WSR
Corporation. He also served as Vice President and CFO of the Genlyte
Group, Inc. Mr. Beshar is a Certified Public Accountant and a graduate
of The Executive Program from the Darden Graduate School of Business,
University of Virginia. He received a BA in Accounting from Michigan
State University. Dendrite is the worldwide leader in sales force and
customer relationship management software and support services to the
global pharmaceutical industry. We deliver solutions that help optimize
the performance of sales, marketing, and clinical resources for our
pharmaceutical clients. More than 70,000 pharmaceutical sales
representatives and managers from over 150 companies and 57 countries
use our products and services. They represent 19 of the top 20
pharmaceutical companies. In fact, two of top three most productive US
pharma sales forces run on Dendrite systems. Dendrite has earned a
worldwide SFA market share of approximately 25% percent. Dendrite
provides a variety of solutions and services to make pharmaceutical
sales forces more effective in the field. Profile
three years?
Mr. Beshar: We anticipate returning to the historical growth rates that
we have enjoyed in the past. Going
